# Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

> **NCT03216096** · PHASE1 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** Placebo ophthalmic solution and 3% DE-089 ophthalmic solution

## Key facts

- **NCT ID:** NCT03216096
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-08
- **Primary completion:** 2018-02-01
- **Final completion:** 2018-02-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216096, "Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03216096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*